Penn Pharma appoints new chief executive
pharmafile | November 30, 2010 | Appointment | Manufacturing and Production, Research and Development | David Cooper, Penn Pharma, Richard Yarwood, appointment, manufacturing and production, research and development
Richard Yarwood has joined pharmaceutical services provider Penn Pharma as chief executive.
He has more than 33 years experience in the pharmaceutical industry and will manage the Welsh firm as it seeks to expand and strengthen its services and international presence.
Richard previously held a number of senior industry positions, including group president of sterile technologies at Catalent Pharma Solutions and president for Europe and Asia Pacific at Catalent, where he managed over 4,000 employees worldwide.
He joins Penn Pharma to head up a 245-strong team and oversee the business in its importation and distribution of clinical trial and commercial material for clients in the UK and internationally.
Penn has also appointed operations director David Cooper to its senior team.
Previously general manager of oral technologies at Zydis, David brings with him extensive experience in global manufacturing from Mylan Pharmaceuticals, formerly Merck Generics.
Mark Molyneux, chairman at Penn Pharmaceutical Services, said: “These are two key appointments for us at Penn Pharma. Both Richard and David will be valuable additions to our board of directors, and their appointments mark another important step as the company rolls out a £12 million expansion programme over the next five years.”
Related Content
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
Lonza CEO to step down in 2020
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …